{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Puvvada SD"],"funding":["NIH/NCI Community Oncology Research Program","Bristol-Myers Squibb","National Cancer Institute","NCI NIH HHS","National Institutes of Health","National Clinical Trials Network"],"pagination":["686-91"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5125530"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["174(5)"],"pubmed_abstract":["Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT."],"journal":["British journal of haematology"],"pubmed_title":["Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704."],"pmcid":["PMC5125530"],"funding_grant_id":["CA180835","UG1 CA189860","CA189872","UG1 CA189954","UG1 CA189953","UG1 CA189854","UG1 CA189952","CA189822","UG1 CA189872","P30 CA060553","CA180819","CA189804","U10 CA180835","U10 CA180838","CA189808","UG1 CA189957","CA180888","CA180821","CA180846","CA180801","U10 CA180819","CA180820","CA180863","CA189860","CA189953","CA189854","UG1 CA189822","CA189952","U10 CA180863","U10 CA180820","CA189954","CA189957","U10 CA180801","U10 CA180846","UG1 CA189808","U10 CA180821","U10 CA180888","UG1 CA189804"],"pubmed_authors":["Leblanc M","Li H","Couban S","Shea TC","Friedberg JW","Puvvada SD","Rimsza LM","Marcellus D","Cook JR","Leonard JP","Stiff PJ","Kahl B","Winter JN","Smith SM"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.","description":"Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Sep","modification":"2025-04-18T20:51:55.459Z","creation":"2019-03-27T02:29:59Z"},"accession":"S-EPMC5125530","cross_references":{"pubmed":["27072903"],"doi":["10.1111/bjh.14100"]}}